Clinical, humanistic, and economic outcomes of gout

Am J Manag Care. 2005 Nov;11(15 Suppl):S459-64; quiz S465-8.


Gout is a low prevalence disease not often considered by managed care organizations with regard to cost management. Understanding the development of the disease and its potential long-term, high-cost consequences can lead to appropriate treatment strategies and cost-management opportunities that can improve patient outcomes and potentially lower the overall cost of treatment of patients with gout in a managed care organization. The acute and chronic nature of the disease is best managed up front to avoid negative long-term effects. Adherence to medications can also impact the manifestation of the disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Aged
  • Causality
  • Cost of Illness*
  • Disease Management
  • Female
  • Global Health
  • Gout / diagnosis
  • Gout / economics*
  • Gout / epidemiology
  • Gout / therapy*
  • Gout Suppressants / therapeutic use
  • Health Behavior
  • Humans
  • Hyperuricemia / epidemiology
  • Male
  • Middle Aged
  • Prevalence
  • Quality of Life*


  • Gout Suppressants